Lava Therapeutics Nv Reports Results For The Quarter Ended December 31: Earnings Summary

LAVA Therapeutics NV

28/03/2025 12:19

LAVA Therapeutics NV LVTX.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -24 cents.  The mean expectation of four analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -47 cents to -15 cents per share.

Revenue rose 1,313.6% to $4.99 million from a year ago; analysts expected $2.50 million.

LAVA Therapeutics NV's reported EPS for the quarter was a loss of 14 cents​.

The company reported a quarterly loss of $3.87 million.

LAVA Therapeutics NV shares had risen by 36.7% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "hold."

Wall Street's median 12-month price target for LAVA Therapeutics NV is $2.00

This summary was machine generated from LSEG data March 28 at 12:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.29
-0.14
Beat
Sep. 30 2024
-0.33
-0.46
Missed
Jun. 30 2024
-0.36
-0.31
Beat
Mar. 31 2024
-0.12
-0.02
Beat